Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate Cancer.

Key Points

• The trial aims to determine whether ctDNA can tailor treatments for metastatic hormone-sensitive prostate cancer, balancing efficacy and safety.
• Conducted with patients diagnosed with metastatic hormone-sensitive prostate cancer.
• Patients with undetectable ctDNA will receive reduced treatment intensity.
• Patients with detectable ctDNA will receive intensified biomarker-matched therapies.
• Aim to preserve treatment outcomes while reducing toxicity.
• Potential for improved quality of life by personalizing therapy based on ctDNA status.